TY - JOUR T1 - Biallelic <em>TET2</em> mutation sensitizes to 5’-azacitidine in acute myeloid leukemia JF - medRxiv DO - 10.1101/2021.07.14.21259597 SP - 2021.07.14.21259597 AU - Friedrich Stölzel AU - Sarah E. Fordham AU - Wei-Yu Lin AU - Helen Blair AU - Claire Elstob AU - Devi Nandana AU - Brigitte Mohr AU - Leo Ruhnke AU - Desiree Kunadt AU - Claudia Dill AU - Daniel Allsop AU - Rachel Piddock AU - Emmanouela-Niki Soura AU - Catherine Park AU - Mohd Fadly AU - Thahira Rahman AU - Abrar Alharbi AU - Manja Wobus AU - Heidi Altmann AU - Christoph Röllig AU - Lisa Wagenführ AU - Gail L. Jones AU - Tobias Menne AU - Graham H. Jackson AU - Helen J. Marr AU - Jude Fitzgibbon AU - Kenan Onel AU - Manja Meggendorfer AU - Olaf Heidenreich AU - Torsten Haferlach AU - Sara Villar AU - Beñat Ariceta AU - Rosa Ayala Diaz AU - Felipe Prosper AU - Pau Montesinos AU - Joaquin Martinez-Lopez AU - Martin Bornhäuser AU - James M. Allan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/18/2021.07.14.21259597.abstract N2 - Precision medicine can significantly improve outcomes for cancer patients, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here we describe somatic biallelic TET2 mutation (focal deletion and nonsense mutation) in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine, but acutely sensitive to 5’-azacitidine (5’-Aza) hypomethylating monotherapy, resulting in long-term morphological remission (overall survival (OS) 850 days). Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5’-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5’-Aza compared to cells with monoallelic mutation. We subsequently identified 29 additional patients from the Study Alliance Leukemia biobank with chromosome 4 abnormalities and identified two further patients with complex biallelic TET2 mutations, including one with trisomy 4, homozygosity across the long arm and an inactivating point mutation. We also screened patients recruited to the PETHEMA FLUGAZA phase 3 clinical trial and identified three patients with biallelic TET2 mutations, two of whom had responded very well to single agent 5’-Aza (OS 767 and 579 days) despite having adverse risk AML and poor performance status. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for cancer patients.Key PointsMutant TET2 allele dosage affects response to 5’-azacitidine in acute myeloid leukemia in vitro and in a xenograft model.Our data highlight the importance for screening of biallelic mutations to predict response to therapy in acute myeloid leukemia.Competing Interest StatementMM is employed by the Munich Leukemia Laboratory and TH is part owner of the Munich Leukemia Laboratory. The remaining authors declare no competing financial interests or conflicts of interest.Clinical TrialNCT02319135Funding StatementThis work was funded by a specialist programme grant from Blood Cancer UK (#13044 to JMA). This work was also supported in part by a grant from the German Consortium for Translational Cancer Research (DKTK) Dresden (to FS), the J.G.W. Patterson Foundation (#30015.088.085/PA/IXS to JMA) and the Accelerator award CRUK/AIRC/AECC joint funder partnership.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:AML patients with an abnormal chromosome 4 (UPN01-UPN30) were from the Study Alliance Leukemia (SAL) AML registry biobank in Dresden (Germany) which was approved by the Institutional Review Board of the Medical Faculty of Dresden (Ethikkomission der TU Dresden, Medizinische Fakultat Dresden; IRB #EK98032010). TET2 mutant patients over 65 years of age with newly diagnosed TET2 mutant AML (UPN31-80) were from the Programa para el Estudio de la Terapeutica en Hemopatias Malignas (PETHEMA) phase 3 FLUGAZA clinical trial (NCT02319135)6, which was approved by the Institutional Review Board of Hospital Le Fe, Valencia, Spain (Eudract=2014-000319-15). Written informed consent was received from all study participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the corresponding authors on request. ER -